

Fig.1a) In vitro proliferation in RPMI medium of (L0) spleen cells stimulated with IL-18 transfected tumor cells for 5 days




FIG. 1A

Fig.1b) In vitro proliferation in RPMI medium of (L0) spleen cells stimulated with 0.1 ng SEA for 3 days




FIG. 1B

Effect of CA4-P low dose treatment of tumor-bearing rats subjected to vaccinations with tumor cells producing IL-18 on spleen cell proliferative response in vitro to wild type tumor (H1D2-WT) or IL-18 transfectant (H1D2-IL-18) stimulator cells.





FIG. 2A

Figure 2B






Figure 3A




Figure 3B




Figure 3C

Figure 4





Figure 5b

Median tumor volume (cubic mm) on day 31.
Immunizations on days 9, 16, 23. CA4(-P) therapy
started on day 7 (2 mg 6 days a week)



Average tumor volume (cubic mm) on day 28. Immunizations on days 10 and 17. Drug therapy started on day 7 (CA4P 5 mg/kg, L-NAME 24 mg x 26 days a week)




FIG. 6